Nucleoside natural products and related analogs with potential therapeutic properties as antibacterial and antiviral agents

Bibliography

• WORLD HEALTH ORGANIZATION: Tuberculosis handbook, WHO, Geneva, Switzerland (1998) (WHO/TB/98.253).
   Google Scholar
• SAPICO FL, MONTGOMERIE JZ, CANAWATI HN: Methicillin-resistant Staphylococcus aureus bacteria. Am. J. Med. (1981) 281:101-109.
   Google Scholar
• HIRAMATSU K: Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Infect. Dis. (2001) 1:147-155.
   Google Scholar
• AKPABIE A, NAGA H, GIRAUD K, AL RR, NADAI S: Resistance to linezolid in Staphylococcus aureus before its release. Pathol. Biol. (2004) 52:493-496.
   PubMedGoogle Scholar
• SILVER LL: Does the cell wall of bacteria remain a viable source of targets for novel antibiotics? Biochem. Pharm. (2006) 996-1005.
   PubMedGoogle Scholar
• GREEN DW: The bacterial cell wall as a source of antibacterial targets. Expert Opin. Ther. Targets (2002) 6:1-19.
   PubMedGoogle Scholar
• ISONO K: Nucleoside antibiotics: structure, biological activity and biosynthesis. J. Antibiot. (1988) 41:1711-1739.
   PubMed Web of Science ®Google Scholar
• ISONO K: Current progress on nucleoside antibiotics. Pharm. Therapeutics (1991) 52:269-286.
   Google Scholar
• KNAPP S: Synthesis of complex nucleoside antibiotics. Chem. Rev. (1995) 95:1859-1876.
   Google Scholar
• ICHIKAWA S, MATSUDA A: Synthesis of complex nucleoside antibiotics. Nucleosides, Nucleotides Nucleic Acids (2005) 24:319-329.
   PubMed Web of Science ®Google Scholar
• KIMURA K, BUGG TD: Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat. Prod. Rep. (2003) 20:252-273.
   PubMed Web of Science ®Google Scholar
• DINI C: MraY inhibitors as novel antibactarial agents. Curr. Topics Med. Chem. (2005) 5:1221-1236.
   Google Scholar
• RACHAKONDA S, CARTEE L: Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics. Curr. Med. Chem. (2004), 11:775-793.
   PubMed Web of Science ®Google Scholar
• TAMURA G: Tunicamycin, Japan Scientific Press: Tokyo (1982).
   Google Scholar
• ISONO K, URAMOTO M, KUSAKABE H et al.: Liposidomycins: novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis. J. Antibiot. (1985) 38:1617-1621.
   PubMed Web of Science ®Google Scholar
• UBUKATA M, KIMURA K, ISONO K, NELSON CC, GREGSON JM, McCLOSKEY JA: Structure elucidation of liposidomycins, a class of complex lipid nucleoside antibiotics. J. Org. Chem. (1992) 57:6392-6403.
   Google Scholar
• UBUKATA M, ISONO K: The structure of liposidomycin B, an inhibitor of bacterial peptidoglycan synthesis. J. Am. Chem. Soc. (1988) 110:4416-4417.
   Google Scholar
• KIMURA K, IKEDA Y, KAGAMI S et al.: Selective inhibition of the bacterial peptidoglycan biosynthesis by the new types of liposidomycins. J. Antibiot. (1998) 51:1099-1104.
   PubMedGoogle Scholar
• MUROI M, KIMURA K, OSADA H, INUKAI M, TAKATSUKI A: Liposidomycin B inhibits in vitro formation of polyprenyl (pyro)phosphate N-acetylglucosamine, an intermediate in glycoconjugate biosynthesis. J. Antibiot. (1997) 50:103-104.
   PubMedGoogle Scholar
• KIMURA K, MIYATA N, KAWANISHI G, KAMIO Y, IZAKI K, ISONO K: Liposidomycin C inhibits phospho-N-acetylmuramyl-pentapeptide transferase in peptidoglycan synthesis of Escherichia coli Y-10. Agric. Biol. Chem. (1989) 53:1811-1815.
   Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A, CLARE BW: Bacterial protease inhibitors. Med. Res. Rev. (2002), 22:329-372.
   PubMed Web of Science ®Google Scholar
• KIMURA K, IKEDA Y, KAGAMI S et al.: New types of liposidomycins that inhibit bacterial peptidoglycan synthesis and are produced by Streptomyces. II. Isolation and structure elucidation. J. Antibiot. (1998) 51:647-654.
   PubMedGoogle Scholar
• KIMURA K, KAGAMI S, IKEDA Y et al.: New types of liposidomycins that inhibit bacterial peptidoglycan synthesis and are produced by Streptomyces. I. Producing organism and medium components. J. Antibiot. (1998) 51:640-646.
   PubMedGoogle Scholar
• IGARASHI M, NAKAGAWA N, DOI N, HATTORI S, NAGANAWA H, HAMADA M: Caprazamycin B, a novel anti-tuberculosis antibiotic, from Streptomyces sp. J. Antibiot. (2003) 56:580-583.
   PubMed Web of Science ®Google Scholar
• IGARASHI M, TAKAHASHI Y, SHITARA T et al.: Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. J. Antibiot. (2005) 58:327-337.
   PubMed Web of Science ®Google Scholar
• HIRANO S, ICHIKAWA S, MATSUDA A: Total synthesis of caprazol, a core structure of the antituberculosis antibiotics, caprazamycins. Angew. Chem. Int. Ed. (2005) 44:1854-1856.
   PubMedGoogle Scholar
• DINI C, COLLETTE P, DROCHON N et al.: Synthesis of nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitor. Bioorg. Med. Chem. Lett. (2000) 10:1839-1843.
   PubMedGoogle Scholar
• DINI C, DROCHON N, GUILLOT JC, MAUVAIS P, WALTER P, ASZODI J: Synthesis of analogues of the O-β-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 2: role of the hydroxyl groups upon the inhibition of MraY. Bioorg. Med. Chem. Lett. (2001) 11:533-536.
   PubMedGoogle Scholar
• DINI C, DROCHON N, FETEANU S, GUILLOT JC, PEIXOTO C, ASZODI J: Synthesis of analogues of the O-β-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY. Bioorg. Med. Chem. Lett. (2001) 11:529-531.
   PubMed Web of Science ®Google Scholar
• DINI C, DIDIER-LAURENT S, DROCHON N et al.: Synthesis of sub-micromolor inhibitors of MraY by exploring the region originally occupied by the diazepanone ring in the liposidomycin structure. Bioorg. Med. Chem. Lett. (2002) 12:1209-1213.
   PubMed Web of Science ®Google Scholar
• HIRANO S, ICHIKAWA S, MATSUDA A: Total synthesis of (+)-FR-900493 and establishment of its absolute stereochemistry. Tetrahedron (2007) 63:2798-2804.
   Google Scholar
• MCDONALD LA, BARBIERI LR, CARTER GT et al.: Structure of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J. Am. Chem. Soc. (2002) 124:10260-10261.
   PubMed Web of Science ®Google Scholar
• LIN Y, LI Z, FRANCISCO GD et al.: Muraymycins, novel peptidoglycan biosynthesis inhibitors: semisynthesis and SAR of their derivatives. Bioorg. Med. Chem. Lett. (2002) 12:2341-2344.
   PubMedGoogle Scholar
• YAMASHITA A, NORTON E, PETERSON PJ et al.: Muraymycins, novel peptidoglycan biosynthesis inhibitors: synthesis and SAR of their analogues. Bioorg. Med. Chem. Lett. (2003) 13:3345-3350.
   PubMed Web of Science ®Google Scholar
• SARABIA F, MARTINORTIZ L: Synthetic studies on nucleoside-type muraymycins antibiotics based on the use of sulfur ylides. synthesis of bioactive 5′-epimuraymycin analogues. Tetrahedron (2005) 61:11850-11865.
   Google Scholar
• YAMAGUCHI H, SATO S, YOSHIDA S et al.: Capuramycin, a new nucleoside antibiotic. taxonomy, fermentation, isolation and characterization. J. Antibiot. (1986) 39:1047-1053.
   PubMedGoogle Scholar
• SETO H, OTAKE N, SATO S et al.: The structure of a new nucleoside antibiotic, capuramycin. Tetrahedron Lett. (1988) 29:2343-2346.
   Google Scholar
• MURAMATSU Y, MURAMATSU A, OHNUKI T et al.: Studies on novel bacterial translocase I inhibitors, A-500359s. taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359 A, C, D and G. J. Antibiot. (2003) 56:243-252.
   PubMed Web of Science ®Google Scholar
• MURAMATSU Y, ARAI M, SAKAIDA Y, TAKAMATSU Y, MIYAKOSHI S, INUKAI M: Studies on novel bacterial translocase I inhibitors, A-500359s. J. Antibiot. (2006) 59:601-606.
   PubMedGoogle Scholar
• HOTODA H, FURUKAWA M, DAIGO M et al.: Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin. Bioorg. Med. Chem. Lett. (2003) 13:2829-2832.
   PubMed Web of Science ®Google Scholar
• CRICK DC, MAHAPATRA S, BRENNAN PJ: Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiolog. (2001) 11:107R-118R.
   Google Scholar
• HOTODA H, DAIGO M, FURUKAWA M et al.: Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds. Bioorg. Med. Chem. Lett. (2003) 13:2833-2836.
   PubMed Web of Science ®Google Scholar
• KOGA T, FUKUOKA T, DOI N et al.: Activity of capuramycin analogues against Mycobacterium tuberculosis, M. avium and M. intracellulare in vitro and in vivo. J. Antibicrob. Chemother. (2004) 54:755-760.
   PubMed Web of Science ®Google Scholar
• INUKAI M, ISONO F, TAKAHASHI S, ENOKITA R, SAKAIDA Y, HANEISHI T: Mureidomycins A – D, novel peptidyl nucleoside antibiotics with speroplast forming activity. I. Taxonomy, fermentation, isolation and physicochemical properties. J. Antibiot. (1989) 42:662-666.
   PubMedGoogle Scholar
• ISONO F, INUKAI M: Mureidomycin A, a new inhibitor of bacterial peptidoglycan synthesis. Antimicrob. Agents Chemother. (1991) 35:234-236.
   PubMedGoogle Scholar
• INUKAI M, ISONO F, TAKATSUKI A: Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins. Antimicrob. Agents Chemother. (1993) 37:980-983.
   Google Scholar
• CHEN RH, BUKO AM, WHITTERN DN, MCALPIN J: Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. II. Iolation and structural elucidation. J. Antibiot. (1989) 42:512-520.
   PubMed Web of Science ®Google Scholar
• FERNANDES PB, SWANSON RN, HARDY DJ et al.: Pacidamycins, a novel series of antibiotics with anti-Pseudomonas aeruginosa activity. III. Microbiologic profile. J. Antibiot. (1989) 42:521-526.
   PubMedGoogle Scholar
• CHATTERJEE S, NADKARNI SR, VIJAYAKUMAR EK et al.: Napsamycins, new pseudomonas active antibiotics of the mureidomycin family from Streptomyces sp. HILY-82, 11372. J. Antibiot. (1994) 47:595-598.
   PubMedGoogle Scholar
• BOOJAMRA CG, LEMOINE RC, NLAIS J et al.: Synthetic dihydropacidamycin antibiotics: a modified spectrum of activity for the pacidamycin class. Bioorg. Med. Chem. Lett. (2003) 13:3305-3309.
   PubMedGoogle Scholar
• TAKEUCHI H, ASAI N, TANABE K et al.: EM2487, a novel anti-HIV-1 antibiotic, produced by Streptomyces sp. Mer-2487: taxonomy, fermentation, biological properties, isolation and structure elucidation. J. Antibiot. (1999) 52:971-982.
   Google Scholar
• WANG X, OKAMOTO M, KAWAMURA M, IZUMO S, BABA M: Inhibition of human T lymphotropic virus type I gene expression by the Streptomyces-derived substance EM2487. Antiviral Chem. Chemother. (2002) 13:177-183.
   Google Scholar
• TAKATSU T, HORIUCHI N, ISHIKAWA M, WANIBUCHI K, MORIGUCHI T, TAKAHASHI S: 1100-50, A novel nematocide from Streptomyces lavendulae SANK 64297. J. Antibiot. (2003) 56:306-309.
   Google Scholar
• TURNER MS, DREW RH, PERFECT JR: Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs (2006), 11:231-250.
   Google Scholar
• HIGASHIYAMA Y, KOHNO S: Micafungin: a therapeutic review. Expert Rev. Anti-Infect. Ther. (2004), 2:345-355.
   Google Scholar